Nov-Dec 2007
Novel Benzothiazine Derivatives
1417
2.95 (s, 3H), 3.67 (q, J = 8 Hz, 2H), 4.25 (q, J = 7.8 Hz, 2H),
7.48 (t, J = 7.6 Hz, 1H), 7.54 (d, J = 7.8 Hz, 1H), 7.64 (t, J = 7.6
Hz, 1H), 7.77 (d, J = 7.8 Hz, 1H); MS (CI): 273(M+H)+.
Product 3c (75%): m.p.: 35-37 ˚C; ꢀH NMR (400 MHz,
DMSO): ꢀ = 0.82 (t, J = 7.6 Hz, 3H), 1.29 (t, J = 7.4 Hz, 3H),
1.46 (m, 2H), 2.95 (s, 3H), 3.56 (br.s, 2H), 4.24 (q, J = 7.8 Hz,
2H), 7.47 (t, J = 7.8 Hz, 1H), 7.55 (s, 1H), 7.63 (t, J = 8.2 Hz,
1H), 7.77 (d, J = 8 Hz, 1H); MS (CI): 287(M+H)+.
Product 3d (oil, 61%): ꢀH NMR (400 MHz, DMSO): ꢀ =
0.92 (t, J = 8.2 Hz, 3H), 1.29 (t, J = 8 Hz, 3H), 1.31 (m, 2H),
1.65 (m, 2H), 2.90 (s, 3H), 4.06 (br.s, 2H), 4.23 (q, J = 7.8 Hz,
2H,), 7.45 (t, J = 7.6 Hz, 1H), 7.60 (d, J = 7.8 Hz, 1H), 7.79 (t, J
= 7.6 Hz, 1H), 7.89 (d, J = 8 Hz, 1H); MS (CI): 300(M+H)+.
Product 3e (oil, 88%): ꢀH NMR (400 MHz, DMSO): ꢀ = 2.92
s, 3H), 5.25 (br.s, 2H), 7.28-7.35 (m, 5H), 7.45 (t, J = 7.8 Hz,
1H), 7.52 (d, J = 7.6 Hz, 1H), 7.61 (t, J = 7.6 Hz, 1H), 7.81 (s,
1H); MS (CI): 334(M+H)+.
11.16; Cl, 12.38; C, 46.08; H, 3.87; N, 9.77; found S, 11.17; Cl,
12.45; C, 46.12; H, 3.91; N, 9.80.
Product 6d (67%): m.p.: 142-143 ˚C; ꢀH NMR (400 MHz,
DMSO): ꢀ = 0.90 (t, J = 6.8 Hz, 3H), 1.28 (sex, J = 6.8 Hz, 2H),
1.61 (q, J = 7 Hz, 2H), 4.01 (t, J = 7.6 Hz, 2H), 7.36 (t, J = 7.8
Hz, 1H), 7.51 (d, J = 7.8 Hz, 1H), 7.63 (t, J = 7.8 Hz, 1H), 7.97
(d, J = 8 Hz, 1H) 8.19 (s, 1H), 12.36 (s, 1H); 13C NMR (100
MHz, DMSO): ꢀ = 13.9, 19.7, 30.6, 47.8, 120.4, 122.5, 125.2,
128.4, 129.7, 133.7, 137.0, 138.5, 141.2; Anal.calcd. S, 10.16;
Cl, 11.27; C, 49.60; H, 4.80; N, 8.90; found S, 10.17; Cl, 11.3;
C, 49.63; H, 4.85; N, 8.92.
Product 6e (62%): m.p.: 210-212 ˚C; ꢀH NMR (400 MHz,
DMSO): ꢀ = 5.22 (s, 2H), 7.20-7.32 (m, 5H), 7.35 (t, J = 7.8 Hz,
1H), 7.41 (d, J = 7.8 Hz, 1H), 7.55 (t, J = 7.6 Hz, 1H), 7.94 (d, J
= 7.8 Hz, 1H), 8.18 (s, 1H), 12.43 (s, 1H); 13C NMR (100 MHz,
DMSO): ꢀ = 50.5, 119.9, 122.1, 124.9, 125.1, 126.3, 126.9,
127.5, 128.0, 129.5, 133.3, 136.9, 138.2, 140.9; Anal. calcd. S,
9.17; Cl, 10.17; C, 49.10; H, 3.96; N, 9.16; found S, 9.17; Cl,
10.18; C, 49.14; H, 4.02; N, 9.19.
4-Chloro-1-alkyl-(1H)-2,1-benzothiazin-3-carbaldehyde-2,2-
dioxide N-phenylhydrazones (7b,e); General Procedure. To a
solution of ꢁ-chloroaldehyde (5b,e) (250 mg, 1 mmol) in ꢀ-PrOH
(2 mL) was added phenylhydrazine (120 mg, 1.2 mmol). The
mixture was heated to reflux for 5 hours. After cooling to rt. the
solid product was filtered and washed with ꢀ-PrOH to afford
pure target compound (68-75%).
Product 7b (75%): ꢀH NMR (400 MHz, DMSO): ꢀ = 1.31 (t,
J = 6.8 Hz, 3H), 4.08 (q, J = 6.8 Hz, 2H), 6.84 (t, J = 7 Hz, 1H),
7.13 (d, J = 7.8 Hz, 2H), 7.235 (t, J = 7.8 Hz ,2H), 7.35 (t, J =
7.6 Hz, 1H), 7.48 (d, J = 7.8 Hz, 1H), 7.56 (t, J = 8 Hz, 1H),
7.94 (d, J = 7.8 Hz, 1H), 7.99 (s, 1H), 11.02 (s, 1H); 13C NMR
(100 MHz, DMSO): ꢀ = 14.7, 44.2, 113.6, 120.3, 121.3, 123.2,
125.2, 127.5, 127.9, 130.0, 131.1, 132.3, 133.0, 137.9, 144.6;
Anal. calcd. S, 8.84; Cl, 9.81; C, 56.43; H, 4.46; N, 11.61; found
S, 8.8; Cl, 9.82; C, 56.47; H, 4.42; N, 11.57.
Product 7e (68%): ꢀH NMR (400 MHz, DMSO): ꢀ = 5.21 (s,
2H), 6.82 (t, J = 6.8 Hz, 2H), 7.12- 7.35 (m, 11H), 7.44 (t, J =
7.8 Hz, 1H), 7.89 (d, J = 7.6 Hz, 1H) 8.0 (s, 1H), 11.0 (s, 1H);
13C NMR (100 MHz, DMSO): ꢀ = 51.6, 113.6, 120.6, 121.3,
123.3, 125.3, 127.5, 127.7, 127.9, 128.4, 128.5, 129.0, 129.3,
130.0, 131.1, 132.1, 133.1, 136.7, 137.8, 144.6; Anal. calcd. S,
7.55; Cl, 8.37; C, 62.33; H, 4.28; N, 9.91; found S, 7.55; Cl, 8.4;
C, 62.31; H, 4.24; N, 9.95.
4-Chloro-3-(1,3-dioxolan-2-yl)-1-alkyl-(1H)-2,1-benzothia-
zin-2,2-dioxides; General Procedure (8b,e). To a mixture of ꢁ-
chloroaldehyde (5b,e) (500 mg, 2 mmol) and ethane-1,2-diol (3
mmol) in dry benzene (15 mL) the catalytic amount of 4-
tolylsulfonic acid (5 mol%) was added. The reaction flask was
equipped with a Dean-Stark trap and the mixture was refluxed
for 5 hours. After cooling to r.t. the organic layer was separated,
washed extensively with water and evaporated in vacuo to afford
yellow solid, which was puified by crystallysation from i-PrOH.
Product 8b (87%): m.p.: 121-123 ˚C; ꢀH NMR (400 MHz,
DMSO): ꢀ = 1.24 (t, J = 7 Hz, 3H), 3.97-4.05 (m, 4H), 4.20 (q,
J = 7.2 Hz, 2H), 6.29 (s, 1H), 7.37 (t, J = 7.8 Hz, 1H), 7.52 (d, J
= 7.6 Hz, 1H), 7.64 (t, J = 7.6 Hz, 1H), 7.98 (d, J = 7.8 Hz, 1H);
13C NMR (100 MHz, DMSO): ꢀ = 14.3, 44.2, 66.4, 100.9, 112.2,
120.5, 122.6, 125.2, 128.5, 132.7, 133.8, 138.9, 139.4; Anal.
calcd. S, 10.13; Cl, 11.24; C, 49.45; H, 4.47; N, 4.44; found S,
10.12; Cl, 11.04; C, 49.49; H, 4.43; N, 4.45.
Product 3f (oil, 78%): ꢀH NMR (400 MHz, DMSO): ꢀ = 2.96
(s, 3H), 5.34 (br.s, 2H), 7.23-7.30 (m, 4H), 7.44 (t, J = 7.6 Hz,
1H), 7.55 (d, J = 7.8 Hz, 1H), 7.63 (t, J = 8 Hz, 1H), 7.83 (d, J =
7.6 Hz, 1H); MS (CI): 368(M+H)+.
N-Alkyl-3,4-dihydro-(1H)-2,1-benzothiazin-4-one-2,2-
dioxides (4a-f), Table 2; General Procedure. To a
magnetically stirred suspension of sodium hydride (120 mmol)
in dry DMF (15 mL) at r.t., the solution of alkylated product
(3a-f) (60 mmol) in dry DMF was added dropwise (25 mL).
After hydrogen evolution was over, the mixture was stirred for 4
hours, DMF was evaporated, and dilute hydrochloric acid (250
mL) was added to the residue. The crude product was collected
by filtered and washed with water. Recrystallisation from i-
PrOH afforded pure target products (67-98%).
4-Chloro-1-alkyl-(1H)-2,1-benzothiazin-3-carbaldehyde-
2,2-dioxides (5a-b,d-e), Table 1; General Procedure. To
magnetically stirred dry DMF (14 mL) at 0 ˚C was added
phosphorus oxychloride (8.3 mL, 40 mmol). After 30 minutes at
0 ˚C the solution of benzothiazine-4-one (4a-b,d-e, 10 mmol) in
dry DMF was added dropwise. The mixture obtained was stirred
for 10 hours, then the temperature was gradually raised to 75 ˚C.
The solution was concentrated in vacuo. To the resulting brown
oil ice was added (250 mL) and the mixture was filtered to yield
pure product (77-97%).
4-Chloro-1-alkyl-(1H)-2,1-benzothiazin-3-carbaldehyde-
2,2-dioxide oximes (6a-b,d-e); General Procedure. To a
solution of ꢁ-chloroaldehyde (5a-b,d-e) (250 mg, 1 mmol) in ꢀ-
PrOH (2 mL) was added hydroxylamine hydrochloride (90 mg,
3 mmol). The mixture was heated to reflux for 3 hours. After
cooling to r.t the solid product was filtered and washed with ꢀ-
PrOH to afford pure target compound (62-89%).
Product 6a (80%): m.p.: 203-205 ˚C; ꢀH NMR (400 MHz,
DMSO): ꢀ = 3.50 (s, 3H), 7.36 (t, J =7.6 Hz, 1H), 7.46 (d, J =
7.8 Hz, 1H), 7.66 (t, J = 8 Hz, 1H), 7.98 (d, J = 7.8 Hz, 1H) 8.19
(s, 1H), 12.37 (s, 1H);
13C NMR (100 MHz, DMSO): ꢀ = 33.0, 119.2, 121.3, 124.9,
128.3, 128.8, 133.9, 137.5, 139.5, 141.3; Anal.calcd. S, 11.73;
Cl, 13.02; C, 44.04; H, 3.33; N, 10.27; found S, 11.75; Cl,
13.02; C, 44.09; H, 3.38; N, 10.32.
Product 6b (89%): m.p.: 179-181 ˚C; ꢀH NMR (400 MHz,
DMSO): ꢀ = 1.30 (t, J = 6.8 Hz, 3H), 4.08 (q, J = 7 Hz, 2H),
7.37 (t, J = 6.8 Hz, 2H), 7.54 (d, J = 7.6 Hz, 1H), 7.66 (t, J = 7.8
Hz, 1H), 7.98 (d, J = 8.2 Hz, 1H) 8.19 (s, 1H), 12.40 (s, 1H);
13C NMR (100 MHz, DMSO): ꢀ = 14.7, 44.2, 120.3, 122.4,
125.2, 128.4, 129.9, 133.7, 137.2, 138.5, 141.3; Anal. calcd. S,
Product 8e (70%): m.p.: 149-151 ˚C; ꢀH NMR (400 MHz,
DMSO): ꢀ = 4.01 (m, 2H), 4.22 (m, 2H), 5.21 (s, 2H), 6.33 (s,